Diaceutics (LON:DXRX) Reaches New 12-Month High - Should You Buy?

Key Points

• Diaceutics hit a new 52-week high, trading intraday as high as GBX 176.76 and last at GBX 173.17 with a volume of 258,460 shares.
• Analysts are bullish: Shore Capital raised its target to GBX 215 and gave a "buy" rating, and the consensus from three analysts is a "Buy" with an average target of GBX 193.33.
• Mixed fundamentals: the company has a market cap of £146.55M, very strong liquidity ratios (quick ratio 9.92, current ratio 3.96) but a negative P/E (-96.20) and a high debt-to-equity of 3.05.

Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 176.76 and last traded at GBX 173.17, with a volume of 258460 shares. The stock had previously closed at GBX 174.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group raised their price target on Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a research report on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Diaceutics currently has an average rating of "Buy" and an average target price of GBX 193.33.

Diaceutics Trading Down 0.5%

The company has a fifty day simple moving average of GBX 153.57 and a two-hundred day simple moving average of GBX 153.45. The company has a quick ratio of 9.92, a current ratio of 3.96 and a debt-to-equity ratio of 3.05. The stock has a market capitalization of £146.55 million, a P/E ratio of -96.20 and a beta of 0.94.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.